How to Cite
Abstract
Safinamide is a novel drug with both dopaminergic and non-dopaminergic effects. Its mechanism works as a selective reversible inhibitor of monoamine oxidase-B approved as a complementary treatment to levodopa in patients with mid-to-late Parkinson's disease and motor fluctuations. Safinamide does not cause new dyskinesia or worsen the existing one but is able to reduce this symptom in these patients.
Keywords
References
Teixeira FG, Gago MF, Marques P, Moreira PS, Magalhães R, Sousa N, et al. Safinamide: a new hope for Parkinson's disease? Drug Discov Today [Internet]. 1 de marzo de 2018 [citado 5 de abril de 2020];23(3):736-44. https://doi.org/10.1016/j.drudis.2018.01.033
Dézsi L, Vécsei L. Safinamide for the treatment of Parkinson's disease. Expert Opin Investig Drugs [Internet]. 1 de mayo de 2014 [citado 5 de abril de 2020];23(5):729-42. https://doi.org/10.1517/13543784.2014.897694
Cattaneo C, Ferla RL, Bonizzoni E, Sardina M. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis. J Park Dis [Internet]. [citado 5 de abril de 2020];5(3):475-81. https://doi.org/10.3233/JPD-150569
Deeks ED. Safinamide: First Global Approval. Drugs [Internet]. 1 de abril de 2015 [citado 5 de abril de 2020];75(6):705-11. https://doi.org/10.1007/s40265-015-0389-7
Martí-Andrés G, Jiménez-Bolaños R, Arbelo-González JM, Pagonabarraga J, Duran-Herrera C, Valenti-Azcarate R, et al. Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study. Brain Sci [Internet]. 11 de octubre de 2019 [citado 5 de abril de 2020];9(10). https://doi.org/10.3390/brainsci9100272
Parkinson's Disease (PD) Mayfield Brain & Spine Cincinnati, Ohio [Internet]. [citado 5 de abril de 2020]. Disponible en: https://mayfieldclinic.com/pe-pd.htm
Mancini F, Di Fonzo A, Lazzeri G, Borellini L, Silani V, Lacerenza M, et al. Real life evaluation of safinamide effectiveness in Parkinson's disease. Neurol Sci [Internet]. 1 de abril de 2018 [citado 5 de abril de 2020];39(4):733-9. https://doi.org/10.1007/s10072-018-3272-y
Stocchi F, Torti M. Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide. Drug Des Devel Ther [Internet]. 5 de febrero de 2016 [citado 5 de abril de 2020];10:609-18. https://doi.org/10.2147/DDDT.S77749
Guía ...la enfermedad de Párkinson [Internet]. Parkinson Burgos. [citado 5 de abril de 2020]. Disponible en: https://www.parkinsonburgos.org/guia-informativa-de-la-enfermedad-de-parkinson/
Martínez-Fernández. R, Gasca-Salas C. C, Sánchez-Ferro Á, Ángel Obeso J. ACTUALIZACIÓN EN LA ENFERMEDAD DE PARKINSON. Rev Médica Clínica Las Condes [Internet]. 1 de mayo de 2016 [citado 5 de abril de 2020];27(3):363-79. https://doi.org/10.1016/j.rmclc.2016.06.010
Marín M DS, Carmona V H, Ibarra Q M, Gámez C M. Enfermedad de Parkinson: fisiopatología, diagnóstico y tratamiento. Rev Univ Ind Santander Salud [Internet]. marzo de 2018 [citado 9 de mayo de 2020];50(1):79-92. https://doi.org/10.18273/revsal.v50n1-2018008
Informe de Posicionamiento Terapéutico de safinamida (Xadago®). En 2018.
Müller T. Emerging approaches in Parkinson's disease - adjunctive role of safinamide. Ther Clin Risk Manag [Internet]. 2 de agosto de 2016 [citado 5 de abril de 2020];12:1151-60. https://doi.org/10.2147/TCRM.S86393
Müller T. Safinamide: an add-on treatment for managing Parkinson's disease. Clin Pharmacol Adv Appl [Internet]. 5 de abril de 2018 [citado 5 de abril de 2020];10:31-41. https://doi.org/10.2147/CPAA.S137740
Bette S, Shpiner D, Singer C, Moore H. Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: A review of the current clinical evidence. Ther Clin Risk Manag. 1 de septiembre de 2018;Volume 14:173745.https://doi.org/10.2147/TCRM.S139545
Perez-Lloret S, Rascol O. The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease. Expert Rev Neurother. 5 de febrero de 2016;16. https://doi.org/10.1586/14737175.2016.1150783
Martínez-Fernández. R, Gasca-Salas C. C, Sánchez-Ferro Á, Ángel Obeso J. ACTUALIZACIÓN EN LA ENFERMEDAD DE PARKINSON. Rev Médica Clínica Las Condes [Internet]. 1 de mayo de 2016 [citado 5 de abril de 2020];27(3):363-79. https://doi.org/10.1016/j.rmclc.2016.06.010
Safinamide. En: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012 [citado 5 de abril de 2020]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK548819/
Müller T, Foley P. Clinical Pharmacokinetics and Pharmacodynamics of Safinamide. Clin Pharmacokinet [Internet]. 1 de marzo de 2017 [citado 5 de abril de 2020];56(3):251-61. https://doi.org/10.1007/s40262-016-0449-5
Baker DE, Kim AP. Formulary Drug Review: Safinamide. Hosp Pharm [Internet]. septiembre de 2017 [citado 5 de abril de 2020];52(8):532-43. https://doi.org/10.1177/0018578717726046
Müller T. Safinamide: an add-on treatment for managing Parkinson's disease. Clin Pharmacol Adv Appl [Internet]. 5 de abril de 2018 [citado 5 de abril de 2020];10:31-41. https://doi.org/10.2147/CPAA.S137740
Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al. Two-Year, Randomized, Controlled Study of Safinamide as Add-on to Levodopa in Mid to Late Parkinson's Disease. Mov Disord. 1 de septiembre de 2014;29. https://doi.org/10.1002/mds.25961
Ossig C, Reichmann H. Treatment Strategies in Early and Advanced Parkinson Disease. Neurol Clin [Internet]. 1 de febrero de 2015 [citado 5 de abril de 2020];33(1):19-37. https://doi.org/10.1016/j.ncl.2014.09.009
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2020 Array